

Women's health

PHIN examines the increasing number of women going private

Transformations

Dr Sayani Sainudeen, new CEO at Transform Healthcare, on growth plans

European dentistry

Which group is likely to become pan-European first?

AUGUST/SEPTEMBER 2024 | VOLUME 28 | ISSUE 7

HM Healthcare Markets

Independent. Intelligent. Insightful.



Indepth

Self-pay

Is demand changing and should we be concerned?

LaingBuisson
INTELLIGENCE + INSIGHT

HM meets... Dr Sayani Sainudeen

Over the last four years, Transform Healthcare has transitioned from a 100% private healthcare business focused on cosmetics and weight loss to a broad based healthcare provider offering a range of services for private and NHS patients. New CEO Dr Sayani Sainudeen talks to HM about the company's journey so far and how he plans to accelerate its transformation plans

HM Can you tell me a bit about your background and how you came into healthcare?

Dr Sayani Sainudeen (SS) My journey into healthcare has been driven by a passion for improving patient outcomes through strategic innovation and growth.

Before joining Transform Healthcare as CEO, I served as an investment director at Y1 Capital, where I focused on healthcare investments mainly in the home care space. This role allowed me to gain a deep understanding of the sector and the challenges faced by healthcare companies, particularly in areas like cosmetic surgery and weight loss services. When the opportunity arose to lead Transform Healthcare, I saw it as a chance to implement a new vision and drive the company towards becoming a broader healthcare services provider. I plan to take a hands-on approach to my role and intend to immerse myself in every department to understand the business at its core so we can deliver our services to best suit the needs of our patients.

How has your transition from investment director at Y1 Capital to CEO of Transform Healthcare been, and what are the biggest challenges you've faced so far?

SS The transition from investment director to CEO has been both challenging and rewarding. One of the biggest challenges has been navigating the complex regulatory environment while steering the company towards new growth opportunities.

However, my background in investment has provided me with a strategic perspective on how to drive sustainable growth and manage risks. Another challenge has been ensuring that our shift towards holistic weight loss services

is executed effectively, particularly as we introduce innovative treatments like GLP-1 agonists and gastric balloons. But I am confident this is something we will be successful in.

You have mentioned a 'new era of innovation and growth' for Transform Healthcare. Can you elaborate on the specific innovations you plan to introduce?

SS One of our key initiatives is expanding our weight loss services to include a wider range of non-surgical treatments.

OUR WORK WITH
THE NHS HAS
SHOWN WHAT WE
CAN DO – FROM
CANCER SURGERY
TO ORTHOPAEDICS
AND GENERAL
SURGERY

Our dedicated weight loss service, which includes a consultation with a GP, a health checkup followed by an option of treatments including weight loss tablets, injections or gastric balloon, will be crucial in the fight against obesity, and in providing safe and effective solution to reduce this. Allurion has developed a new

technology which is a gastric balloon that does not require surgery or endoscopy – it comes as a tablet which is swallowed under medical supervision or x-ray control. Transform gained the status of being a centre of excellence for Allurion, becoming one of the largest providers for gastric balloons. We have carried out more than 600 procedures so far.

Transform has launched a ten-point plan aimed at enhancing affordability, accessibility, and quality of care? What does this involve and how will it develop over time?

SS We are currently working on a strategy on making our procedures more affordable, to be launched in the coming weeks. In terms of accessibility, we've added clinics and hospitals to our network so that more people can see us in different locations.

Transform Healthcare played a significant role during the Covid-19 pandemic. How did this experience shape the company's long-term strategy and its transition from a cosmetic treatment business into broader healthcare delivery?

SS Prior to Covid, we were 100% a private healthcare company. Now we're a mixed model of private care and NHS patients. We're very proud to support the NHS and help to bring down waiting lists, and we make ourselves continually available to NHS. This has made a clear impact and has also allowed us to extend services, such as bariatric surgeries. Going forward, given the size of the waiting lists and the challenges the NHS has, we see Transform, alongside the entire private sector, being constantly ready to deliver vital services.



HM meets...
Dr Sayani Sainudeen

CEO, Transform Healthcare

Career

CEO and Medical Director,
Transform Healthcare (2024–present)
Group CEO & Medical Director,
Signature Clinic (2019–present)
Investment Director and Shareholder,
Y1 Capital Ltd (2015–present)

Education

Royal College of General Practitioners,
Master's Degree, MRCGP (2006–2010)
University of Science and Technology,
Chittagong, Bachelor's Degree, Medicine
(1996–2003)

www.linkedin.com/in/dr-sayani-sainudeen-b739137/